论文部分内容阅读
目的探讨NAFLD临床病理改变与血清内脏脂肪素(visfatin)、脂联素(adiponectin)水平的相关性。方法取54例患者肝组织标本,根据其病理改变分为正常对照组(Control组)、单纯性脂肪肝组(SS组)、非酒精性脂肪性肝炎(NASH组)。酶联免疫法测定所有患者的血清visfatin、adiponectin水平,并比较各组之间visfatin、adiponectin的差异。结果 54例标本中:Control组23例,SS组11例,NASH组20例。NASH组血清visfatin低于Control组(P=0.012)和SS组(P=0.021);SS组血清visfatin较Control组有降低的趋势;Control组血清adiponectin高于NASH组(P=0.024)和SS组(P=0.039);NASH组较SS组有降低的趋势。结论在NAFLD患者中,随着肝组织脂肪变及炎症的加重,其血清visfatin、adiponectin水平逐渐降低。
Objective To investigate the correlation between the clinicopathological changes of NAFLD and visfatin and adiponectin in serum. Methods Totally 54 patients were divided into control group, simple fatty liver group (SS group) and non-alcoholic steatohepatitis (NASH group) according to their pathological changes. Serum levels of visfatin and adiponectin in all patients were determined by enzyme-linked immunosorbent assay (ELISA). The differences of visfatin and adiponectin in each group were compared. Results Of 54 specimens, 23 were in Control group, 11 in SS group and 20 in NASH group. The serum visfatin in NASH group was lower than that in Control group (P = 0.012) and SS group (P = 0.021). The serum visfatin in SS group was lower than that in Control group. The adiponectin level in Control group was higher than that in NASH group and SS group (P = 0.039). There was a trend of decrease in NASH group compared with SS group. Conclusion In patients with NAFLD, the levels of visfatin and adiponectin in serum gradually decrease with the increase of hepatic steatosis and inflammation.